Pusic I, Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host disease after failure of frontline corticosteroids: results of a multicenter open-label phase 2-study. EHA 2017, S492.
Moet ibrutinib de nieuwe standaard worden bij de behandeling van CLL?
apr 2020 | Leukemie